Finding antibodies to protect against Crimean-Congo Hemorrhagic Fever
Official title: Isolation of broadly protective monoclonal antibodies for Crimean Congo Hemorrhagic Fever
Funded at University of Maryland Baltimore · NIH-10981217 · Data updated 2026-11-12
This study is looking at how to use antibodies from people who have survived Crimean-Congo Hemorrhagic Fever to help protect others from the virus, and it’s for anyone interested in finding new ways to fight this serious illness.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Maryland Baltimore NIH-funded |
| Lab location | 1 site (Baltimore, United States) |
| Project start | July 23, 2024 |
| Project end | June 30, 2029 |
| Funding year | 2024 |
| Award (this year) | $685,980 |
| NIH project number | 1R01AI180125-01A1 |
| Project ID | NIH-10981217 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals who have survived Crimean-Congo Hemorrhagic Fever.
✕Less likely to help
Patients who have not been infected with Crimean-Congo Hemorrhagic Fever are unlikely to benefit from this research.
What this research studies
This research focuses on Crimean-Congo Hemorrhagic Fever (CCHF), a serious viral infection with no current vaccine or specific treatment. The team aims to isolate monoclonal antibodies from survivors of CCHF, which may provide broad protection against the virus. By analyzing blood samples from CCHF survivors in Turkey, they will identify antibodies that can neutralize the virus effectively. The research will also test these antibodies in a mouse model to evaluate their protective capabilities.
Why it matters
Potential benefit: If successful, this research could lead to the development of effective treatments for CCHF, potentially saving lives.
How similar studies have gone: Previous research has shown promise in isolating protective antibodies from survivors of viral infections, indicating potential success for this approach.
Where this research is happening
-
University of Maryland Baltimore
Baltimore, United States Active
Researchers
- Principal investigator: Sajadi, Mohammad Mohseni — University of Maryland Baltimore
- Study coordinator: Sajadi, Mohammad Mohseni
Related research
Other NIH-funded projects on the same topics.
-
Broad antiviral drugs that target coronaviruses and other viruses
A research program aims to identify small molecules that can block multiple viruses, focusing first on coronaviruses, to help create drugs that can treat future outbreaks.
-
Finding broadly protective antibodies against Crimean-Congo Hemorrhagic Fever
Researchers will study blood from people who survived CCHF to find human antibodies that protect against multiple virus variants, with early tests in animal models to check their breadth.
-
Antivirals for hemorrhagic fever viruses like LASV, SFTSV, and EBOV
A multi-institutional effort to find and validate antiviral compounds that block key viral proteins from LASV, SFTSV, and EBOV to help people at risk from serious hemorrhagic fevers.
-
A New Model for Valley Fever: Studying Coccidioides Infection with Volatile Clues in Wax Moths
Researchers are testing a new, cheaper model using wax moths to study Valley Fever caused by Coccidioides, with the goal of understanding how the infection behaves and how it could be diagnosed or treated.
-
Halogen-modified nucleoside analogs to fight yellow fever virus
Aims to develop new oral medicines that could prevent or treat yellow fever by using specially modified building blocks that stop the virus from growing.
-
Understanding Guanarito virus and building countermeasures for Venezuelan hemorrhagic fever
This project studies how Guanarito virus causes disease and aims to develop vaccines or treatments to protect people in areas where Venezuelan hemorrhagic fever occurs.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.